Ultragenyx Pharmaceutical Inc. (RARE) — Analyst outlook / Analyst consensus target is. Based on 33 analyst ratings, the consensus is bullish — 27 Buy, 5 Hold, 1 Sell.
The consensus price target is $49.90 (low: $34.00, high: $63.00), representing an upside of 103.1% from the current price $24.57.
Analysts estimate Earnings Per Share (EPS) of $-6.19 and revenue of $0.55B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-6.29 vs est $-6.19 (missed -1.6%). 2025: actual $-5.83 vs est $-5.60 (missed -4.1%). Analyst accuracy: 97%.
RARE Stock — 12-Month Price Forecast
$49.90
▲ +103.09% Upside
Average Price Target
Based on 33 Wall Street analysts offering 12-month price targets for Ultragenyx Pharmaceutical Inc., the average price target is $49.90, with a high forecast of $63.00, and a low forecast of $34.00.
The average price target represents a +103.09% change from the last price of $24.57.
Highest Price Target
$63.00
Average Price Target
$49.90
Lowest Price Target
$34.00
RARE Analyst Ratings
Buy
Based on 33 analysts giving stock ratings to Ultragenyx Pharmaceutical Inc. in the past 3 months
EPS Estimates — RARE
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$6.29
vs Est –$6.19
▼ 1.6% off
2025
Actual –$5.83
vs Est –$5.60
▼ 3.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — RARE
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.560B
vs Est $0.548B
▲ 2.3% off
2025
Actual $0.673B
vs Est $0.665B
▲ 1.2% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
